IRulya Therapeutics Inc. stock analysis IRLA.US

Quince Therapeutics, Inc. is a late-stage biotechnology company that develops treatments for rare diseases using its proprietary AIDE (Autologous Intracellular Drug Encapsulation) platform. The core business centers on the drug/device combination platform which encapsulates drugs into a patient's own red blood cells through an automated process. Its lead candidate, eDSP (formerly EryDex), uses that platform to deliver dexamethasone sodium phosphate encapsulated in autologous red blood cells to treat the rare pediatric neurodegenerative disorder Ataxia-Telangiectasia.

In addition to its lead asset, Quince pursues expansion of its pipeline through acquisition and in-licensing of clinical-stage assets in rare and debilitating disease areas. The company acquired EryDel in October 2023 to secure eDSP and the AIDE platform. It formerly pursued a bone-targeting drug platform, including NOV004 for skeletal indications, though its current business depends heavily on the development and regulatory success of eDSP.

Quince Therapeutics operates primarily out of South San Francisco, California, with additional research or manufacturing presence in Italy (Medolla and Bresso). It has no approved products on the market and no revenues from product sales. Its business model is focused on developing novel therapeutics through clinical trials and securing regulatory approval. As of early 2026 the Phase 3 NEAT trial for eDSP failed to meet its primary endpoint, which presents a material challenge to its lead program.